Q-omics provides the consensus-scored ANAPC1P1 profile across patient tissues and cancer cell-line models. ANAPC1P1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ANAPC1P1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ANAPC1P1 RNA expression shows 15,114 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where ANAPC1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANAPC1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANAPC1P1 survival associations across molecular data types. ANAPC1P1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANAPC1P1 RNA expression–survival associations across cancer types. High ANAPC1P1 expression shows unfavorable associations in KIRC, COAD, KICH and LUAD, but favorable associations in HNSC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ANAPC1P1 RNA expression.
This table summarizes ANAPC1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANAPC1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANAPC1P1 shows higher tumor expression in HNSC, KIRC, COAD, UCEC, LUAD and LIHC. The HNSC box plot shows higher ANAPC1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p = .001).
This table shows molecular features associated with ANAPC1P1 in patient tissues and cancer cell lines. In patient samples, ANAPC1P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
